What Synaffix BV does

Synaffix BV is a Dutch biotechnology company founded in Oss, Netherlands, that develops a site-specific antibody-drug conjugate (ADC) technology platform for oncology and other therapeutic applications. The company's core offering comprises three proprietary technologies: GlycoConnect®, which enables site-specific attachment of linker-payloads to antibodies through enzymatic glycan engineering and allows precise control of drug-antibody ratio (DAR1, DAR2, DAR4); HydraSpace®, a polar spacer technology bearing negative charge at physiological pH that improves therapeutic efficacy, tolerability, pharmacokinetics, and manufacturability; and toxSYN®, a linker-payload portfolio covering topoisomerase 1 inhibitors (SYNtecan E™), DNA damaging agents (SYNeamicin D™/G™, SYN-PNU™), microtubule inhibitors (SYNstatin E™/F™), and maytansine-based payloads (SYNtansine™). The platform has been expanded to include dual-payload ADC technology, which addresses tumor heterogeneity and resistance, and a Protein Conjugates capability spanning scFv/Fab fragments, cytokines, and immune cell recruiters (anti-CD3, IL-15, IL-15 receptor fusion).

Synaffix operates a technology licensing business model, granting pharmaceutical and biotech partners access to its platform under multi-target agreements in exchange for upfront payments, clinical, regulatory, and commercial milestone payments, plus royalties on net sales of resulting products. Partners retain responsibility for research, development, manufacturing, and commercialization of their own ADC candidates. The platform has been adopted by named partners including Sidewinder Therapeutics (bispecific ADCs in solid tumors) and BigHat Biosciences (next-generation ADC at IND-enabling stage), with customer evidence pointing to pharma and biotech segments developing ADC therapeutics for solid tumors, colorectal, squamous cell carcinoma, and gastrointestinal cancers.

In 2023, Synaffix was acquired by Lonza and subsequently fully integrated into Lonza's Advanced Synthesis business platform, with the Synaffix website now redirecting to lonza.com. The integration positions the platform inside Lonza's global end-to-end ADC offering, providing access to commercial bioprocess infrastructure and worldwide reach. The Oss, Netherlands R&D site has been expanded through additional laboratory infrastructure investment, and the platform's IP has been reinforced through filed patents on SYNtecan E™, SYNeamicin D™/G™, and SYN-PNU™ alongside registered trademarks for GlycoConnect®, HydraSpace®, and toxSYN®.

Name

Synaffix BV

Legal name

Synaffix BV

Website

https://synaffix.com

Company type

Private

Founded year

2012

Operating status

Acquired

Headcount range

11–50 employees

Short description

Synaffix BV licenses a proprietary site-specific ADC technology platform (GlycoConnect, HydraSpace, toxSYN) to pharma and biotech companies developing antibody-drug conjugates for cancer. Now a wholly-owned Lonza subsidiary integrated into Advanced Synthesis.

Ownership category

akta.pro rank

Product category

Antibody-Drug Conjugate (ADC) Technology Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Antibody-drug conjugates
• ADC technology platform
• Bioconjugation technology
• Linker-payload systems
• Site-specific conjugation

Headquarters

HQ city

Oss

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Technology Licensing: Synaffix licenses its ADC technology platform to pharmaceutical and biotech companies for development of ADC therapeutics. Revenue is generated through upfront payments, clinical, regulatory, and commercial milestone payments, plus royalties on net sales of approved products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Synaffix BV licenses a proprietary site-specific antibody-drug conjugate (ADC) technology platform to pharmaceutical and biotechnology companies. The platform comprises GlycoConnect® (enzymatic conjugation technology enabling precise drug-antibody ratio control), HydraSpace® (polar spacer technology), and toxSYN® (a portfolio of linker-payloads spanning multiple mechanisms of action). Partners access the platform to develop ADC therapeutics for oncology indications.

Product overview

Synaffix BV, now fully integrated into Lonza's Advanced Synthesis business platform, offers a comprehensive site-specific ADC technology platform consisting of three core proprietary technologies: GlycoConnect® for antibody conjugation, HydraSpace® for polar spacers, and toxSYN® for linker-payloads. Together, these technologies enable precise control of drug-antibody ratio and payload selection for ADC development. The platform has been expanded to include dual-payload ADC technology and supports protein conjugates including peptide and cytokine-based payloads. The company provides access to its technology through licensing agreements and end-to-end ADC development and manufacturing services.

Differentiator

Problem solved

Functional benefit

Brands

• GlycoConnect®: Antibody conjugation technology enabling site-specific, uniform conjugation of payloads to antibodies.
• HydraSpace®
• toxSYN®

Products and services

• GlycoConnect® Site-specific antibody conjugation technology that enables precise control of drug-antibody ratio (DAR1, DAR2, DAR4) through enzymatic glycan engineering on antibodies. Licensed to pharma and biotech companies developing ADC therapeutics.
• HydraSpace® Polar Spacer Proprietary polar spacer technology forming an integral part of every toxSYN® linker-payload, bearing a negative charge at physiological pH to improve therapeutic efficacy, tolerability, pharmacokinetics, and manufacturability.
• toxSYN® Linker-Payload Portfolio Licensed portfolio of linker-payloads covering multiple modes of action including SYNtecan E™ (camptothecin-based topoisomerase 1 inhibitor), SYNeamicin D™/G™ (calicheamicin-based DNA damaging agents), SYN-PNU™ (nemorubicin-based), SYNstatin E™/F™ (auristatin-based microtubule inhibitors), and SYNtansine™ (maytansine-based). Supports DAR1, DAR2, and DAR4 configurations.
• Dual-Payload ADC Technology Advanced ADC technology enabling attachment of two different payloads to a single antibody, designed to address tumor heterogeneity and drug-induced resistance mechanisms. Licensed as part of the Synaffix/Lonza ADC platform.
• Protein Conjugates Platform Capability to attach peptide and protein-based payloads to antibodies, including scFv/Fab fragments, cytokines (IL-15), and immune cell recruiters (anti-CD3 for T-cell recruitment, IL-15 receptor fusion for NK cell recruitment). Licensed to partners for preclinical ADC and bioconjugate development.

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Sidewinder TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 7 January 2026Synaffix (Lonza) and Sidewinder Therapeutics entered a multi-target licensing agreement granting Sidewinder access to Lonza's clinically validated, site-specific ADC technology platform including GlycoConnect®, HydraSpace®, and toxSYN® linker payload technologies to develop first-in-class bispecific ADC therapeutics for solid tumor indications. Lonza eligible for upfront, clinical, regulatory, and commercial milestone payments plus royalties on net sales. Sidewinder responsible for research, development, manufacturing, and commercialization.
• BigHat BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 4 November 2024Synaffix (Lonza) licensed its ADC technology to BigHat Biosciences for development of a new ADC pipeline combining Synaffix's platform with BigHat's AI/ML-powered antibody design platform (Milliner). The collaboration advances BigHat's next-generation ADC program which is at IND-enabling stage and aims to improve safety and efficacy. BigHat gains access to Lonza's end-to-end ADC offering for drug development and manufacturing.
• LonzacoreOthers · 1 January 2023Lonza acquired Synaffix in 2023 and has fully integrated the ADC technology platform into its Advanced Synthesis business platform. The platform now includes GlycoConnect®, HydraSpace®, toxSYN® linker payloads, and dual-payload ADC technology. Lonza expanded its Oss, Netherlands site through increased laboratory infrastructure investment.

Scale indicators1 record

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• ImmunoGen (AbbVie): ImmunoGen, acquired by AbbVie in 2024, is a pioneer in ADC technology with approved products and a portfolio of in-house linker-payload and conjugation platforms. As a major incumbent ADC technology owner, it competes with Synaffix on licensing partnerships and represents the established benchmark for ADC platform economics.
• Pfizer (Seagen): Pfizer acquired Seagen in 2023, gaining a leading ADC commercial and development platform including approved products (Adcetris, Padcev, Tukysa) and proprietary payload/conjugation technology. It is a broad incumbent that competes for ADC licensing partners and shapes market pricing benchmarks for ADC platforms.
• AstraZeneca: AstraZeneca has built a major ADC franchise through partnerships (e.g., Daiichi Sankyo) and internal investment, including the Enhertu collaboration and additional ADC pipeline programs. It is a large incumbent licensing partner/customer and competitor in the ADC technology space relevant to Synaffix.
• Daiichi Sankyo: Daiichi Sankyo is a Japanese pharma major and a global ADC leader with multiple approved ADCs (Enhertu, Datroway) using proprietary DXd payload technology. As a broad incumbent in the ADC space, it shapes partner expectations for platform performance and royalty terms that Synaffix must match or exceed.

Direct peers

• Heidelberg Pharma: Heidelberg Pharma is a German ADC technology platform company offering its proprietary ATAC (Antibody Targeted Amanitin Conjugate) linker-payload platform for licensing to pharma and biotech partners. It is the most direct peer to Synaffix given the parallel technology-licensing business model and shared focus on differentiated payload chemistries.
• WuXi XDC: WuXi XDC is a leading global ADC contract development and manufacturing organization (CDMO) spun out of WuXi Biologics, offering integrated discovery, development, and manufacturing services for ADCs. It competes directly with the integrated Lonza/Synaffix offering, particularly for partners seeking a one-stop ADC outsourcing solution.
• Mersana Therapeutics: Mersana Therapeutics is a US clinical-stage biotech developing proprietary ADC platforms including Dolasynthen and Immunosynthen. It competes with Synaffix for pharma licensing partners seeking differentiated payload and conjugation technologies, though Mersana is more product-focused than purely platform-focused.
• Byondis: Byondis is a Netherlands-based ADC-focused biotech developing proprietary site-specific conjugation chemistries (e.g., HydraSpace-derived technology lineage) and linker-payloads. Its technology and Dutch origins make it one of the closest functional competitors to Synaffix's platform.

Emerging players

• Bolt Biotherapeutics: Bolt Biotherapeutics is a clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) that couple tumor-targeting antibodies with immune agonists. It is an emerging adjacent player in next-generation bioconjugate therapeutics with overlapping payload-innovation themes to Synaffix's dual-payload and protein conjugate work.

Others

• Lonza Bioconjugates: Lonza Bioconjugates is Synaffix's parent business unit within Lonza's Advanced Synthesis platform, providing the end-to-end ADC manufacturing infrastructure that Synaffix's technology now plugs into. It is included as a relevant adjacent/parent context rather than a competitor, illustrating the scale of the manufacturing footprint backing Synaffix licensing deals.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/Synaffix
• LinkedInlinkedin.com/company/synaffix-bv

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synaffix BV